Andy Chen
Stock Analyst at Wolfe Research
(3.85)
# 762
Out of 4,414 analysts
17
Total ratings
18.18%
Success rate
38.97%
Average return
Main Sectors:
Top Industries:
14 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALPN Alpine Immune Sciences | Downgrades: Peer Perform | n/a | $64.60 | - | 3 | Apr 11, 2024 | |
| IONS Ionis Pharmaceuticals | Upgrades: Outperform | n/a | $43.09 | - | 1 | Apr 10, 2024 | |
| MLTX MoonLake Immunotherapeutics | Initiates: Outperform | n/a | $42.57 | - | 1 | Feb 15, 2024 | |
| CRSP CRISPR Therapeutics AG | Initiates: Peer Perform | n/a | $55.07 | - | 1 | Feb 15, 2024 | |
| ALNY Alnylam Pharmaceuticals | Initiates: Peer Perform | n/a | $150.31 | - | 1 | Feb 15, 2024 | |
| KYMR Kymera Therapeutics | Initiates: Peer Perform | n/a | $36.30 | - | 1 | Feb 15, 2024 | |
| ROIV Roivant Sciences | Initiates: Outperform | $17 | $11.24 | +51.25% | 1 | Feb 15, 2024 | |
| IMVT Immunovant | Initiates: Outperform | $55 | $28.78 | +91.10% | 1 | Feb 15, 2024 | |
| NTLA Intellia Therapeutics | Initiates: Peer Perform | n/a | $23.27 | - | 1 | Feb 15, 2024 | |
| VRTX Vertex Pharmaceuticals | Initiates: Outperform | n/a | $400.16 | - | 1 | Feb 15, 2024 | |
| ARGX argenx SE | Initiates: Peer Perform | n/a | $393.42 | - | 1 | Feb 15, 2024 | |
| INSM Insmed | Initiates: Outperform | $42 | $25.66 | +63.68% | 1 | Feb 15, 2024 | |
| RAPT RAPT Therapeutics | Initiates: Outperform | $39 | $8.13 | +380.00% | 2 | Feb 15, 2024 | |
| AFMD Affimed | Assumes: Buy | $60 | $5.30 | +1,032.08% | 1 | Aug 8, 2023 |
Alpine Immune Sciences
Apr 11, 2024
Downgrades: Peer Perform
Price Target: n/a
Current: $64.60
Upside: -
Ionis Pharmaceuticals
Apr 10, 2024
Upgrades: Outperform
Price Target: n/a
Current: $43.09
Upside: -
MoonLake Immunotherapeutics
Feb 15, 2024
Initiates: Outperform
Price Target: n/a
Current: $42.57
Upside: -
CRISPR Therapeutics AG
Feb 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $55.07
Upside: -
Alnylam Pharmaceuticals
Feb 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $150.31
Upside: -
Kymera Therapeutics
Feb 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $36.30
Upside: -
Roivant Sciences
Feb 15, 2024
Initiates: Outperform
Price Target: $17
Current: $11.24
Upside: +51.25%
Immunovant
Feb 15, 2024
Initiates: Outperform
Price Target: $55
Current: $28.78
Upside: +91.10%
Intellia Therapeutics
Feb 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $23.27
Upside: -
Vertex Pharmaceuticals
Feb 15, 2024
Initiates: Outperform
Price Target: n/a
Current: $400.16
Upside: -
argenx SE
Feb 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $393.42
Upside: -
Insmed
Feb 15, 2024
Initiates: Outperform
Price Target: $42
Current: $25.66
Upside: +63.68%
RAPT Therapeutics
Feb 15, 2024
Initiates: Outperform
Price Target: $39
Current: $8.13
Upside: +380.00%
Affimed
Aug 8, 2023
Assumes: Buy
Price Target: $60
Current: $5.30
Upside: +1,032.08%